Great Valley Advisor Group Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,546 shares of the medical research company’s stock after purchasing an additional 109 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Thermo Fisher Scientific were worth $450,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ellevest Inc. raised its position in Thermo Fisher Scientific by 137.5% in the second quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 55 shares during the period. American National Bank purchased a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $29,000. Massey Quick Simon & CO. LLC purchased a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $30,000. Candriam Luxembourg S.C.A. raised its position in Thermo Fisher Scientific by 11.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 104,069 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 10,569 shares during the period. Finally, Redhawk Wealth Advisors Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $31,000. 88.21% of the stock is currently owned by institutional investors.
A number of brokerages have issued reports on TMO. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Credit Suisse Group reissued a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Needham & Company LLC boosted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Robert W. Baird upped their price objective on Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $314.45.
Thermo Fisher Scientific stock opened at $299.90 on Tuesday. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The stock’s fifty day simple moving average is $289.23 and its 200-day simple moving average is $282.06. The company has a current ratio of 1.80, a quick ratio of 1.07 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $117.52 billion, a P/E ratio of 26.97, a P/E/G ratio of 1.90 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping analysts’ consensus estimates of $2.88 by $0.06. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The business had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. During the same quarter in the prior year, the company earned $2.62 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.33 earnings per share for the current year.
In related news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total value of $500,280.69. Following the transaction, the director now owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 2,271 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the completion of the transaction, the chief executive officer now directly owns 283,502 shares in the company, valued at approximately $84,483,596. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: Most Volatile Stocks
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.